Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · IEX Real-Time Price · USD
29.52
+0.09 (0.31%)
Apr 19, 2024, 3:59 PM EDT - Market closed
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AGIO stock have an average target of 35.5, with a low estimate of 28 and a high estimate of 42. The average target predicts an increase of 20.26% from the current stock price of 29.52.
Analyst Consensus: Buy
* Price targets were last updated on Feb 23, 2024.
Analyst Ratings
The average analyst rating for AGIO stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 9, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $31 → $30 | Hold | Maintains | $31 → $30 | +1.63% | Feb 23, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $43 → $42 | Buy | Maintains | $43 → $42 | +42.28% | Feb 16, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $32 → $28 | Hold | Maintains | $32 → $28 | -5.15% | Nov 3, 2023 |
| JP Morgan | JP Morgan | Hold Maintains $33 → $32 | Hold | Maintains | $33 → $32 | +8.40% | Aug 7, 2023 |
Financial Forecast
Revenue This Year
43.50M
from 26.82M
Increased by 62.17%
Revenue Next Year
115.97M
from 43.50M
Increased by 166.60%
EPS This Year
-5.92
from -6.33
EPS Next Year
-6.00
from -5.92
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 65.8M | 286.7M | 365.9M | 684.5M | 997.5M |
| Avg | 43.5M | 116.0M | 201.5M | 483.0M | 635.2M |
| Low | 30.4M | 64.1M | 118.9M | 205.4M | 266.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 145.3% | 559.0% | 215.5% | 239.6% | 106.5% |
| Avg | 62.2% | 166.6% | 73.8% | 139.7% | 31.5% |
| Low | 13.3% | 47.3% | 2.5% | 1.9% | -44.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.18 | -3.30 | -1.39 | 0.79 | 5.57 |
| Avg | -5.92 | -6.00 | -4.55 | 0.44 | 2.60 |
| Low | -6.99 | -8.62 | -6.66 | 0.11 | -0.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 1,168.8% |
| Avg | - | - | - | - | 491.9% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.